Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix Tablets for Heavy Menstrual Bleeding Associated With Uterine Fibroids
CTR20254952Phase 3Active
- Sponsor
- Heze Pharma
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing Relugolix 40 mg once daily with Placebo once daily (2 arms). Primary endpoint: Responder rate for menstrual blood loss at Week 12. Started Dec 2025; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on CTR20254952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254952.